DK3927370T3 - Fremgangsmåder til frembringelse af autologe T-celler, der kan anvendes til cancerbehandling, og sammensætninger deraf - Google Patents

Fremgangsmåder til frembringelse af autologe T-celler, der kan anvendes til cancerbehandling, og sammensætninger deraf Download PDF

Info

Publication number
DK3927370T3
DK3927370T3 DK20711461.2T DK20711461T DK3927370T3 DK 3927370 T3 DK3927370 T3 DK 3927370T3 DK 20711461 T DK20711461 T DK 20711461T DK 3927370 T3 DK3927370 T3 DK 3927370T3
Authority
DK
Denmark
Prior art keywords
compositions
cells
methods
cancer treatment
generating autologous
Prior art date
Application number
DK20711461.2T
Other languages
English (en)
Inventor
Timothy J Langer
Jacob Ceccarelli
Original Assignee
Turnstone Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turnstone Biologics Corp filed Critical Turnstone Biologics Corp
Application granted granted Critical
Publication of DK3927370T3 publication Critical patent/DK3927370T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61K39/4611—
    • A61K39/4632—
    • A61K39/464401—
    • A61K39/464499—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
DK20711461.2T 2019-02-19 2020-02-18 Fremgangsmåder til frembringelse af autologe T-celler, der kan anvendes til cancerbehandling, og sammensætninger deraf DK3927370T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962807644P 2019-02-19 2019-02-19
US201962826974P 2019-03-29 2019-03-29
US201962941614P 2019-11-27 2019-11-27
US201962941610P 2019-11-27 2019-11-27
PCT/US2020/018711 WO2020172202A1 (en) 2019-02-19 2020-02-18 Methods for producing autologous t cells useful to treat cancers and compositions thereof

Publications (1)

Publication Number Publication Date
DK3927370T3 true DK3927370T3 (da) 2024-05-21

Family

ID=69811963

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20711461.2T DK3927370T3 (da) 2019-02-19 2020-02-18 Fremgangsmåder til frembringelse af autologe T-celler, der kan anvendes til cancerbehandling, og sammensætninger deraf

Country Status (13)

Country Link
US (1) US20220135944A1 (da)
EP (2) EP4394032A3 (da)
KR (1) KR20210152464A (da)
CN (1) CN113710270A (da)
AU (1) AU2020226498A1 (da)
BR (1) BR112021016340A2 (da)
CA (1) CA3130578A1 (da)
DK (1) DK3927370T3 (da)
ES (1) ES2980469T3 (da)
IL (1) IL285631A (da)
MX (1) MX2021009967A (da)
PT (1) PT3927370T (da)
WO (1) WO2020172202A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230032934A1 (en) * 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
CN114901805B (zh) 2020-11-19 2023-07-25 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的培养方法及其用途
US20240043801A1 (en) * 2020-12-24 2024-02-08 Suzhou Grit Biotechnology Co., Ltd. Preparation method for tumor infiltrating lymphocyte and use thereof
CN116426483B (zh) * 2021-12-30 2024-02-23 南京紫珑生物科技有限公司 Cd258蛋白在免疫治疗中的应用
WO2023218399A1 (en) 2022-05-11 2023-11-16 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Method of preparing and expanding a population of immune cells for cancer therapy, potency assay for tumor recognition, biological vaccine preparation and epitope target for antibodies
WO2024098041A1 (en) * 2022-11-04 2024-05-10 Turnstone Biologics Corp. Compositions and methods for generating neo-antigen reactive tumor infiltrating lymphocytes
WO2024130212A1 (en) 2022-12-16 2024-06-20 Turnstone Biologics Corp. Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985565A (en) 1996-10-09 1999-11-16 Temple University-Of The Commonwealth System Of Higher Education Chronic fatigue syndrome diagnosis
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
LT4209510T (lt) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
SI2504364T1 (sl) 2009-11-24 2017-11-30 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
KR102218512B1 (ko) 2010-05-25 2021-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ｂａｍｂａｍ：고처리율 서열분석 데이터의 병렬 비교 분석
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
PT2785375T (pt) 2011-11-28 2020-10-29 Merck Patent Gmbh Anticorpos anti-pd-l1 e usos destes
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
DK3200818T3 (da) 2014-10-02 2022-08-22 Us Health Fremgangsmåder til isolering af t-cellereceptorer med antigen specificitet over for en cancer-specifik mutation
WO2018183485A1 (en) * 2017-03-31 2018-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating neoantigen-specific t cell receptor sequences

Also Published As

Publication number Publication date
EP3927370B8 (en) 2024-06-05
PT3927370T (pt) 2024-06-03
EP4394032A3 (en) 2024-10-02
BR112021016340A2 (pt) 2021-10-26
AU2020226498A1 (en) 2021-10-14
EP3927370B1 (en) 2024-04-24
EP3927370A1 (en) 2021-12-29
EP4394032A2 (en) 2024-07-03
CN113710270A (zh) 2021-11-26
MX2021009967A (es) 2021-11-12
WO2020172202A1 (en) 2020-08-27
CA3130578A1 (en) 2020-08-27
ES2980469T3 (es) 2024-10-01
IL285631A (en) 2021-09-30
US20220135944A1 (en) 2022-05-05
KR20210152464A (ko) 2021-12-15

Similar Documents

Publication Publication Date Title
DK3927370T3 (da) Fremgangsmåder til frembringelse af autologe T-celler, der kan anvendes til cancerbehandling, og sammensætninger deraf
DK3102609T3 (da) Fremgangsmåder til fremstilling af autologe T-celler, der kan anvendes til at behandle B-celle-maligniteter og andre cancerformer, og sammensætninger deraf
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
IL282735A (en) Preparations and methods for t-cell engineering
PH12020551923A1 (en) Methods and compositions for treating cancer
DK3775091T3 (da) Stabiliserede fluorolefinsammensætninger og fremgangsmåder til fremstilling, oplagring og anvendelse deraf
IL280659A (en) Processes for creating transgenic cells and their compounds
EA201992781A1 (ru) Ингибиторы g12c kras и способы их применения
DK3331900T3 (da) Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere
DK3291830T3 (da) Hidtil ukendte peptider og kombination af peptider og stilladser deraf til anvendelse ved immunterapi mod kolorektalt karcinom og andre cancere
DK3402483T3 (da) Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
DK3322425T3 (da) Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
DK3842429T3 (da) Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer
DK3430030T5 (da) Transficerede t-celler og t-cellereceptorer til anvendelse i immunoterapi mod cancer
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3902803T3 (da) Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3775165T3 (da) Fremgangsmåder til frembringelse af tumorinfiltrerende lymfocytter og anvendelser heraf i immunterapi
DK3319985T3 (da) Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod øsofaguscancer og andre cancere
DK3102232T3 (da) Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst
MX2020003605A (es) Manipulación del metabolismo de triptamina.
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3496743T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler
DK3460052T3 (da) Forbedrede allogene dendrittiske celler til anvendelse i behandling af cancer
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer